

KERYX BIOPHARMACEUTICALS INC
Form 10-Q/A
November 13, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission File Number 000-30929

KERYX BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 13-4087132

(State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.)

One Marina Park Drive, 12th Floor

Boston, Massachusetts 02210

(Address including zip code of principal executive offices)

(617) 466-3500

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files): Yes No

EXPLANATORY NOTE

This Amendment No. 1 on Form 10-Q/A (the “Amendment”) is an amendment to Keryx Biopharmaceuticals, Inc.’s (the “Registrant”) Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 (the “Report”) filed with the Securities and Exchange Commission on November 8, 2018. The Registrant is filing this Amendment for the sole purpose of correcting an inadvertent transposition error on the cover page of the Report in the number of shares of the Registrant’s common stock, \$0.001 par value, outstanding as of October 31, 2018, which should be 120,375,926 instead of 102,375,926. In addition, the Registrant is also including Exhibits 31.1 and 31.2 with this Amendment. This Amendment does not alter any other part of the content of the Report and does not affect the information originally set forth in the Report, the remaining portions of which have not been amended.

ITEM 6. EXHIBITS

The following exhibits are included with this Amendment:

Exhibit Number	Exhibit Description
-------------------	---------------------

31.1	<u>Certification of Interim Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 9, 2018</u>
------	--

31.2	<u>Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 9, 2018</u>
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KERYX BIOPHARMACEUTICALS, INC.

Date: November 9, 2018 By: /s/ Scott A. Holmes

Scott A. Holmes

Chief Financial Officer

Principal Financial and Accounting Officer